In a new study, scientists showed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection provokes immunoglobulin A (IgA)-associated vasculitis (IgAV).
The manufacturer of olokizumab is expected to file for approval in the United States early next year, and the drug could add a new option for patients for whom methotrexate alone doesn t work.
us. just as a point, because it s just interesting, he was the one who essentially founded one of the really, you know, disease altering treatments for a condition called vasculitis. so for me, i always looked to him as sort of this unbelievable mentor, if you will, to the health care masses, and, you know, to your point, what he s had to go through over the last, you know, couple of years, it s painful to watch because, you know, in his words, i hear such a sincerity, you know, and altruism. that s how i m going to remember him. but he said, you know, his career is not over. he s opening up yet another chapter and will continue to provide guidance and a vision for all the people under him who are looking to him, you know, as
CANBERA (dpa-AFX) - Vifor Fresenius Medical Care Renal Pharma said that England's National Institute for Health and Care Excellence or NICE has recommended Tavneos in combination with a rituximab